期刊文献+

Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt 被引量:1

Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt
下载PDF
导出
摘要 AIM: To assess hepatic fibrosis and factors associated with its progression in children with HCV infection. METHODS: At the Hepatology Unit,Cairo University Children's Hospital,a single liver biopsy was performed to 43 children with HCV infection after an informed consent between 1998-2004. Their mean age at liver biopsy was 8.67 ± 4.3 years. RESULTS: Among the 43 patients' biopsies,12 (27.9%) were having no fibrosis,20 (46.5%) mild fibrosis and 11 (25.6%) moderate to severe fibrosis. The median time for development of fibrosis was estimated to be 5.5 years. Developing fibrosis was significantly associated with shorter duration from first detected ALT elevation to biopsy (12 mo vs 1.2 mo,P = 0.015) and having higher levels of direct serum bilirubin (0.3 mg/dL vs 0.5 mg/dL,P = 0.048). No association was found between fibrosis stage and the presence of co-morbid conditions (P = 0.33). CONCLUSION: Hepatic fibrosis was present in 72.1% of children with HCV infection. The development of fibrosis was associated with higher levels of direct serum bilirubin. There was no significant association between fibrosis and age,duration of infection,risk factors,co-morbid conditions and most biochemical parameters. AIM: To assess hepatic fibrosis and factors associated with its progression in children with HCV infection. METHODS: At the Hepatology Unit, Cairo University Children's Hospital, a single liver biopsy was performed to 43 children with HCV infection after an informed consent between 1998-2004. Their mean age at liver biopsy was 8.67 ± 4.3 years. RESULTS: Among the 43 patients' biopsies, 12 (27.9%) were having no fibrosis, 20 (46.5%) mild fibrosis and 11 (25.6%) moderate to severe fibrosis. The median time for development of fibrosis was estimated to be 5.5 years. Developing fibrosis was significantly associated with shorter duration from first detected ALT elevation to biopsy (12 mo vs 1.2 mo, P = 0.015) and having higher levels of direct serum bilirubin (0.3 mg/dL vs 0.5 mg/dL, P = 0.048). No association was found between fibrosis stage and the presence of co-morbid conditions (P = 0.33). CONCLUSION: Hepatic fibrosis was present in 72.1% of children with HCV infection. The development of fibrosis was associated with higher levels of direct serum bilirubin. There was no significant association between fibrosis and age, duration of infection, risk factors, comorbid conditions and most biochemical parameters.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第20期2846-2851,共6页 世界胃肠病学杂志(英文版)
关键词 CHILDREN EGYPT FIBROSIS Hepatitis C virus LIVER 肝纤维化 儿童 丙型病毒肝炎 埃及
  • 相关文献

参考文献45

  • 1[1]Abdel-Wahab MF,Zakaria S,Kamel M,Abdel-Khaliq MK,Mabrouk MA,Salama H,Esmat G,Thomas DL,Strickland GT.High seroprevalence of hepatitis C infection among risk groups in Egypt.Am J Trop Med Hyg 1994; 51:563-567
  • 2[2]Chamberlain RW,Adams N,Saeed AA,Simmonds P,Elliott RM.Complete nucleotide sequence of a type 4 hepatitis C virus variant,the predominant genotype in the Middle East.J Gen Virol 1997; 78:1341-1347
  • 3[3]WHO.Hepatitis C:global prevalence.Wkly Epidemiol Rec 1997;72:341-344
  • 4[4]Poynard T,Bedossa P,Opolon P.Natural history of liver fibrosis progression in patients with chronic hepatitis C.The OBSVIRC,METAVIR,CLINIVIR,and DOSVIRC groups.Lancet 1997; 349:825-832
  • 5[5]Seeff LB.Natural history of hepatitis C.Hepatology 1997; 26:21S-28S
  • 6[6]Danta M,Dore GJ,Hennessy L,Li Y,Vickers CR,Harley H,Ngu M,Reed W,Desmond PV,Sievert W,Farrell GC,Kaldor JM,Batey RG.Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection.Med J Aust 2002; 177:240-245
  • 7[7]Marcellin P,Asselah T,Boyer N.Fibrosis and disease progression in hepatitis C.Hepatology 2002; 36:S47-S56
  • 8[8]Kleiner DE.The liver biopsy in chronic hepatitis C:a view from the other side of the microscope.Semin Liver Dis 2005; 25:52-64
  • 9[9]National Institutes of Health Consensus Development Conference Panel statement Management of hepatitis C.Hepatology 1997; 26:2S-10S
  • 10[10]National Institutes of Health Consensus Development Conference Statement Management of Hepatitis CJune10-12,2002.Hepatology 2002; 36:S3-S20

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部